September 24, 2019
A Massachusetts federal judge tapped wholesaler Rochester Drug Co-Operative on Tuesday to lead a class alleging that pharmaceutical companies Shire and Actavis conspired to delay the entry of a generic form of Shire's ADHD drug Intuniv, despite Rochester's criminal problems over opioid sales.
August 21, 2019
A Massachusetts federal judge on Wednesday refused to grant class certification to two classes of parents and caretakers accusing the pharmaceutical companies Actavis and Shire of antitrust violations, saying they delayed sale of the ADHD medication Intuniv, causing consumers to pay inflated prices.
July 26, 2019
Pharmaceutical distributor Rochester Drug Co-Operative, which admitted to unlawful opioid sales earlier this year, argued in Boston federal court Friday that it is reformed and can dutifully serve as a class representative in an antitrust pay-for-delay suit over the sales of ADHD medication Intuniv.
December 10, 2018
Shire LLC will have to turn over documents in an antitrust suit accusing it and Actavis of settling a patent dispute over an ADHD drug on anti-competitive terms, a Massachusetts federal judge ruled Monday.
November 28, 2018
Rochester Drug Cooperative won't be able to dodge questions about a federal investigation into opioid sales during upcoming depositions in its proposed class action accusing Actavis LLC and Shire LLC of settling a patent dispute over an ADHD drug on anti-competitive terms, a Massachusetts federal judge ruled Tuesday.
November 02, 2018
Hagens Berman Sobol Shapiro LLP pursued lead counsel status and class certification Friday in a proposed antitrust case against two pharmaceutical companies over the marketing of ADHD drug Intuniv, according to a filing in Massachusetts federal court.
August 29, 2017
A recent decision by the Third Circuit reviving a pay-for-delay suit over Effexor XR has no bearing on litigation by purchasers of Intuniv alleging Actavis LLC and Shire LLC made an illegal agreement to delay generic competition for the attention deficit hyperactivity disorder medication, Actavis said Tuesday.
May 11, 2017
Direct purchasers of the attention deficit hyperactivity disorder medication Intuniv on Wednesday urged a Massachusetts federal court not to dismiss their antitrust case against Actavis LLC and Shire LLC, arguing that there was an illegal reverse payment and that the companies misconstrued precedent.
April 11, 2017
A patent dispute settlement between Actavis LLC and Shire LLC over ADHD medication Intuniv was not an illegal reverse payment and an antitrust lawsuit by purchasers of the drug should be dismissed, the companies told a Massachusetts federal court Monday.